Concerto HealthAI, a SymphonyAI Group portfolio company, is innovating in real world data (RWD) and AI solutions for precision oncology.
The company’s mission is to bring together unique data assets, AI-based technologies, and top outcomes research and data science talent. Concerto HealthAI’s focus is on revolutionizing clinical and outcomes research to accelerate the insights benefiting patient treatment.
Earlier this year, the company announced that it has entered into a multi-disease collaboration with Janssen Research & Development, LLC (Janssen). The collaboration will allow Janssen to access Concerto HealthAI’s use-case engineered RWD, enterprise AI solutions, and scientific services. Concerto HealthAI has the most comprehensive, representative, and independently sourced RWD in the industry as part of an exclusive licensing agreement with the American Society of Clinical Oncology’s CancerLinQ® program, and partnerships with clinically integrated community oncology networks, and other partners.
Janssen gains access to Concerto HealthAI’s suite of use-case engineered RWD products in the new eurekaHealth 3.0 enterprise AI solution. eurekaHealth integrates and enriches multiple sources to provide a holistic view of the patient journey with greater clinical depth to support translational sciences, clinical study design, and RWD applications for regulatory submissions. eurekaHealth 3.0 is the only enterprise-grade solution to exceed 21CFRPart11 compliance requirements and serve as an intelligence layer, integrating into research and clinical development workflows across the enterprise. Janssen will be the first to use Concerto HealthAI’s Genome360™, a translational-grade, first-in-class, real-world solution in development that integrates in-depth clinical and next-generation sequencing characterization of a patient’s cancer.
In January, the company announced an expansion of its existing precision oncology collaboration with Pfizer Oncology to advance Concerto HealthAI’s use-case engineered RWD. The collaboration is for an array of clinical development initiatives across breast, lung, prostate and renal cell carcinoma cancers that will drive innovative new study designs and non-interventional studies.
This collaboration, first announced in early 2019, builds on the success of the current use of Concerto HealthAI’s RWD to now also include claims data linked to clinical EMR data and linked next-generation sequence panel data for both research and potential regulatory purposes. Pfizer will also be one of the earliest adopters of Concerto HealthAI’s RWE enterprise solution, eurekaHealth 3.0, that provides the industry’s first integration of RWD and AI-enabled tools and models within an analytic cloud environment.
Financing
Also in January, Concerto HealthAI announced a $150 million series B round that was led by Declaration Partners with additional backing from Maverick Ventures, AllianceBernstein PCI and SymphonyAI Group. The proceeds is slated to leverage the company’s innovation work and services for regulated and non-regulated applications, as well as its expansions into additional therapy areas and commercial patient solutions, according to the company’s announcement.
